Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients With Moderate to Severe Endometriosis-related Pain - the NOVA Trial

NCT07260669 is registered in ClinicalTrials.gov with Gesynta Pharma AB as lead sponsor.

NCT NCT07260669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07260669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients With Moderate to Severe Endometriosis-related Pain - the NOVA Trial
Lead sponsor
Gesynta Pharma AB
Phase
Phase 2
Overall status
Recruiting
Start date
October 15, 2025
Completion date
June 30, 2027
Enrollment
190 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis